Successful combined treatment with omalizumab and tocilizumab in a case of chronic spontaneous urticaria and rheumatoid arthritis: A case report and literature review

Nao Takeuchi, Ayumi Yamanishi, Yoshiko Kumagai, Tomoaki Yokoyama

Article ID: 1443
Vol 6, Issue 2, 2022, Article identifier:1-3

VIEWS - 552 (Abstract) 202 (PDF)


Omalizumab is a recombinant humanized monoclonal anti-IgE antibody used to treat uncontrolled chronic spontaneous urticaria (CSU). Sometimes patients with CSU also have other autoimmune conditions. Recent studies have demonstrated the safety and efficacy of a combination treatment with omalizumab and other biologics. Here, we report the first successful treatment with omalizumab for CSU and tocilizumab for rheumatoid arthritis. Since omalizumab is unlikely to cause severe immunosuppression, it may be a treatment option for CSU, even in patients treated with other biologics.


Chronic Spontaneous Urticaria; Omalizumab; Rheumatoid Arthritis; Tocilizumab; Anti-IL-6 Receptor Antibody

Full Text:



Diluvio L, Vollono L, Zangrilli A, et al. Omalizumab and adalimumab: A winning couple. Immunoltherapy 2020; 12(8): 1287–1292. doi: 10.2217/imt-2020-0203

Fougerousse AC, Becherel PA, Pallure V, et al. Combining omalizumab with another biotherapy. Acta Dermto-Venereologica 2019; 99(4): 448–449. doi: 10.2340/00015555-3140

Ghazanfar MN, Thomsen SF. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis. Journal of Dermatological Treatment 2019; 30(4): 387–388. doi: 10.1080/09546634.2018.1515465

Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology 2014; 133(5): 1365–1372. doi: 10.1016/j.jaci.2013.12.1076

Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Annals of the Rheumatic Diseases 2007; 66(2): 228–234. doi: 10.1136/ard.2006.055111

Rubini NPM, Ensina LFC, Silva EMK, et al. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergologia et Immunopatologia 2019; 47: 515–522. doi: 10.1016/j.aller.2019.05.003

Diluvio L, Pensa C, Piccolo A, et al. Tildrakizumab and omalizumab: An interlocking therapy for autoimmune conditions. Journal of Clinical Images and Medical Case Reports 2021; 2(4): 1251. doi: 10.1111/dth.15359



  • There are currently no refbacks.

Copyright (c) 2022 Nao Takeuchi, Ayumi Yamanishi, Yoshiko Kumagai, Tomoaki Yokoyama

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.